πŸ”¬Deep Research

ALLO β€” Allogene Therapeutics Inc Β· catalysts, narrative & risks

Β·27 sourcesALLO forecast β†’

Company Snapshot

Allogene Therapeutics, Inc. (NASDAQ: ALLO) is a clinical-stage biotechnology company headquartered in South San Francisco developing allogeneic ("off-the-shelf") chimeric antigen receptor (CAR) T cell productsβ€”marketed as "AlloCAR T"β€”for blood cancers, solid tumors, and autoimmune disease [1] [4] [20]. It was founded in 2018, with founders including David Chang and Arie Belldegrun [1] [25]. As of ~October 22, 2026, ALLO traded near $1.25–1.33, with a market capitalization around $432 million and roughly 345 million shares outstanding [19] [20]. The stock has a 52-week range of $1.04–$4.46 and a beta of 0.56 [19] [20].


AI-assisted research from the K3vl4r desk β€” not personalized investment advice. More research β†’